- Home
- CUE vs CGTX Comparison
CUE vs CGTX Comparison
Compare CUE & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- CGTX
- Stock Information
- Founded
- CUE 2014
- CGTX 2007
- Country
- CUE United States
- CGTX United States
- Employees
- CUE N/A
- CGTX N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- CUE Health Care
- CGTX Health Care
- Exchange
- CUE Nasdaq
- CGTX Nasdaq
- Market Cap
- CUE 59.5M
- CGTX 53.4M
- IPO Year
- CUE 2018
- CGTX 2021
- Fundamental
- Price
- CUE $0.72
- CGTX $1.47
- Analyst Decision
- CUE Strong Buy
- CGTX Strong Buy
- Analyst Count
- CUE 2
- CGTX 3
- Target Price
- CUE $3.00
- CGTX $2.83
- AVG Volume (30 Days)
- CUE 132.0K
- CGTX 8.1M
- Earning Date
- CUE 11-13-2025
- CGTX 11-12-2025
- Dividend Yield
- CUE N/A
- CGTX N/A
- EPS Growth
- CUE N/A
- CGTX N/A
- EPS
- CUE N/A
- CGTX N/A
- Revenue
- CUE $8,286,000.00
- CGTX N/A
- Revenue This Year
- CUE N/A
- CGTX N/A
- Revenue Next Year
- CUE $13.27
- CGTX N/A
- P/E Ratio
- CUE N/A
- CGTX N/A
- Revenue Growth
- CUE N/A
- CGTX N/A
- 52 Week Low
- CUE $0.45
- CGTX $0.22
- 52 Week High
- CUE $1.99
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- CUE 34.73
- CGTX 39.92
- Support Level
- CUE $0.77
- CGTX $1.43
- Resistance Level
- CUE $0.78
- CGTX $2.60
- Average True Range (ATR)
- CUE 0.03
- CGTX 0.31
- MACD
- CUE -0.01
- CGTX -0.19
- Stochastic Oscillator
- CUE 9.53
- CGTX 2.94
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.